ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Monogram Presents Results Of First ETag Breast Cancer Studies
Monogram
Biosciences, Inc. (Nasdaq: MGRM) today announced that two presentations
detailing initial studies on the clinical utility of its proprietary eTag
technology in metastatic breast cancer will be presented at the 43rd
American Society of Clinical Oncology (ASCO) meeting (June 1-5) in Chicago,
Illinois. A third presentation will describe the molecular characterization
of cell lines that have acquired resistance to the breast cancer drug
Herceptin (trastuzumab). Currently under development, the eTag technology
is a highly advanced diagnostic platform for quantifying protein
expression, protein-protein interactions (e.g. receptor dimerization) and
protein modification (e.g. phosphorylation). This unique capability enables
the eTag technology to accurately assess signaling pathways that control
cell growth, proliferation and survival. Dysregulation of these pathways
has been associated with a wide variety of tumors, including breast, lung,
prostate and colorectal cancers. Many new therapeutic candidates target
various steps in these critical cell signaling pathways, potentially
providing an opportunity for the diagnostic capabilities of the eTag
technology to improve patient treatment and drug development.
The presentations at the ASCO meeting describe the Company's progress
in addressing two critical questions related to the treatment of HER2(+)
breast cancer patients. First, why don't all HER2(+) breast cancers respond
equally well to targeted therapy with Herceptin. And second, why do many
HER2(+) breast cancers develop resistance to Herceptin treatment. The
presentations are:
- "Differential survival following trastuzumab treatment based on
quantitative HER2 expression and HER2-HER2 dimerization in a clinic-
based cohort of patients with metastatic breast cancer."
(Poster 12 / Abstract 1025, presented Saturday, June 2, 8:00 a.m. -
12:00 p.m., Room S403)
- "HER2 expression and HER2-HER2 dimerization identifies subpopulations of
metastatic breast cancer patients with different probabilities of long-
term survival following trastuzumab treatment and with different
requirements for concomitant chemotherapy"
(Poster JJ5, Abstract 10557, presented Sunday, June 3, 8:00 a.m. - 12:00
p.m., S Hall A2)
- Patterns of HER-family receptor dimerization in trastuzumab susceptible
and trastuzumab resistant cell lines
(Poster A3, Abstract 2533, presented Sunday, June 3, 8:00 a.m. - 12:00
p.m., S Hall A2)
"The eTag platform represents a powerful new tool for advancing
personalized medicine in cancer treatment," said Monogram CEO Bill Young.
"By providing quantitative measurements to characterize disease at the
molecular level and by detecting the protein complexes to help accurately
predict an individual patient's response to specific therapies, eTag
technology may empower oncologists with the critical information needed to
improve patients' lives and may help drive the development of more
effective targeted cancer therapies."
About the eTag System
Monogram's eTag assays enable detailed analysis of protein drug targets
and signaling pathways in cancer cells, using tissue lysates or FFPE
specimens, which is the standard format in most pathology labs. The assays
can provide information on a drug's mechanism of action, selectivity and
potency in a biological setting in pre-clinical research, and enable
selection of clinical trial populations later in a drug's development. In
addition, Monogram believes these assays may ultimately be used to help
physicians better determine whether certain therapies are more appropriate
for individual cancer patients, and whether to combine therapies with
different mechanisms or properties. The first commercially available
activated receptor test panel based on eTag technology will be focused on
the EGFR/HER receptor family.
About Monogram Biosciences, Inc.
Monogram is advancing individualized medicine by discovering,
developing and marketing innovative products to guide and improve treatment
of serious infectious diseases and cancer. The Company's products are
designed to help doctors optimize treatment regimens for their patients
that lead to better outcomes and reduced costs. The Company's technology is
also being used by numerous biopharmaceutical companies to develop new and
improved antiviral therapeutics and vaccines as well as targeted cancer
therapeutics. More information about the Company and its technology can be
found on its web site at http://www.monogrambio.com.
Forward Looking Statements
Certain statements in this press release are forward-looking, including
statements regarding the ability of assays based on the eTag technology to
predict individual patient response to targeted cancer therapies. These
forward-looking statements are subject to risks and uncertainties and other
factors, which may cause actual results to differ materially from the
anticipated results or other expectations expressed in such forward-looking
statements. These risks and uncertainties include, but are not limited to,
risks and uncertainties relating to the performance of our products;
whether measurement of dimerization or protein pathway activation are key
indicators in determining individual patient response; our ability to
obtain additional cohorts of patient samples for additional studies, our
ability to successfully conduct clinical studies and the results obtained
from those studies; whether larger confirmatory clinical studies will
confirm the results of initial studies; whether the results of studies
conducted with patient samples treated with a particular targeted cancer
therapy will be representative of results with other targeted therapies;
whether clinical data derived from these studies will be adequate to
support the commercial introduction of a test for patient responsiveness to
targeted cancer therapies; the timing and launch of eTag assays for patient
use; our ability to establish reliable, high-volume operations at
commercially reasonable costs; the development of competitive technologies;
actual market acceptance of our products and adoption of our technological
approach and products by pharmaceutical and biotechnology companies; our
estimate of the size of our markets; our estimates of the levels of demand
for our products; the timing and ultimate size of pharmaceutical company
clinical trials; whether payors will authorize reimbursement for its
products; whether the FDA or any other agency will decide to regulate
Monogram's products or services; whether the draft guidance on Multivariate
Index Assays recently issued by FDA applies to our current or planned
products; the ultimate validity and enforceability of our patent
applications and patents; the possible infringement of the intellectual
property of others; whether licenses to third party technology will be
available; and whether Monogram is able to build brand loyalty and expand
revenues.. For a discussion of other factors that may cause Monogram's
actual events to differ from those projected, please refer to the Company's
most recent annual report on Form 10-K and quarterly reports on Form 10-Q,
as well as other subsequent filings with the Securities and Exchange
Commission. We do not undertake, and specifically disclaim any obligation,
to revise any forward-looking statements to reflect the occurrence of
anticipated or unanticipated events or circumstances after the date of such
statements.
Monogram Biosciences, Inc.
http://www.monogrambio.com
View drug information on Herceptin.
Monogramã prezinta rezultatele din prima ETag studii de cancer de sân - Monogram Presents Results Of First ETag Breast Cancer Studies - articole medicale engleza - startsanatate